Mesoblast Ltd has released a press release.
Mesoblast Update on Chronic Low Back Pain Program
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Mesoblast
- MSB Reports Q3 Financial Results and Operational Highlight
- COVID ARDS Trial Topline 60-Day Results
- Mesoblast Raises US$110M Led By US Strategic Investor Group
- Mesoblast Phase 3 Chronic Low Back Pain Results
- Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
Later from Mesoblast
- MSB Annual Financial Results and Operational Progress
- AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
- MSB and Oaktree Conclude Refinancing of Senior Debt Facility
- Update on Novartis Agreement
- FDAs OTAT Agrees to Primary Endpoint for Back Pain
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast